UAE R&D incentives force a rethink on where innovation activity should be located
As countries compete to attract research and development activity, the United Arab Emirates has moved quickly to position itself as a viable location for innovation through newly introduced R&D tax incentives. That policy shift is prompting multinational corporations, investor-backed start-ups and life sciences firms to reassess not only whether to claim incentives, but where to place the teams, intellectual property and supporting functions that underpin R&D.
Policy change, broader questions
Tax incentives are one element in strategic decisions about where to carry out R&D. Increasingly, companies must balance straightforward tax arithmetic with questions about operational substance, transfer pricing, intellectual property ownership and alignment with long-term commercial plans. The UAE’s incentive regime adds a fresh option to a landscape already shaped by European and Asian credit systems, national tax credits, and global anti-base erosion rules.
The consequence is a more nuanced decision-making process. For some groups, shifting R&D activity to jurisdictions that offer enhanced cash or tax benefits can reduce effective tax costs. For others, the costs of relocating staff, building local capability, or migrating IP may outweigh the headline tax benefits. The right choice depends on business model, scale of R&D spend, investor expectations and the regulatory environment in relevant jurisdictions.
Practical considerations for multinational groups
There are a number of practical issues finance and tax teams need to assess when considering whether to locate R&D in the UAE or elsewhere.
Substance and staffing: Tax authorities increasingly look beyond the legal form of arrangements to whether real economic activity and decision-making take place in the jurisdiction claiming the incentive. Firms should evaluate whether they can establish credible local teams, governance and management processes that align with the claimed R&D activity.
Intellectual property and ownership: Where IP is created, managed and owned affects transfer pricing, tax residence and investor perceptions. Moving IP to secure a tax advantage can trigger scrutiny under controlled-foreign-company rules and transfer-pricing adjustments in other jurisdictions.
Cross-border group structuring: Multinational groups must model the interaction between the UAE regime and existing incentive regimes in Europe or Asia, withholding tax rules, and broader international rules such as OECD initiatives on tax base erosion. Structuring choices also affect cash flow, reporting and the legal framework around commercialization of new technologies.
Scalability and long-term positioning: Short-term incentives can be attractive, but boards and investors will want a clear plan for scaling operations and maintaining continuity if policies change. Location decisions that make sense at one stage may need revision as businesses mature.
Implications for sectors and investors
Technology companies, life sciences firms and investor-backed enterprises are particularly sensitive to where R&D sits because of the link between innovation, valuation and exit outcomes. For venture-backed companies, ease of hiring talent, access to specialized labs or cloud infrastructure, and clear IP ownership rules can matter as much as the headline tax treatment.
For strategic or corporate R&D centres, proximity to markets and ecosystems—universities, incubators and supply chains—remains a key driver. Incentives are likely to be decisive only when they complement an operational case for locating teams in a jurisdiction.
What to watch for
Tax and finance leaders should monitor a few developments closely as they form policies and make investment choices:
Regulatory guidance and audits: How local tax authorities implement and audit the incentive regime will shape its practical value. Clear guidance on eligibility, documentation requirements and interactions with other incentives reduces compliance risk.
International tax developments: Ongoing global reforms, including measures aimed at preventing profit-shifting, will influence the net benefit of relocating R&D. Companies must consider how incentives interact with international tax rules and bilateral tax treaties.
Operational readiness: The ability to recruit, manage and retain R&D personnel locally will determine the feasibility of relocating activity. Talent availability and immigration rules are therefore part of the calculus.
Decision framework for boards and finance leaders
At a minimum, companies should undertake a structured assessment that compares the total economic benefit of locating R&D in the UAE with alternative jurisdictions. That analysis should quantify tax and cash benefits, account for setup and ongoing operating costs, and evaluate the non-tax commercial advantages and risks. Scenario planning that captures policy changes and audit risk can help executives present a defensible position to investors and regulators.
For teams preparing to revisit their R&D footprint, targeted discussions with tax advisers, legal counsel and HR leads are essential. In the near term, many organisations will find that a hybrid model—maintaining core discovery capabilities in existing hubs while colocating certain development activities where incentives are strongest—offers a pragmatic compromise.
Practical next steps include mapping current R&D spend, reviewing IP arrangements, stress-testing transfer-pricing positions, and preparing documentation that demonstrates substantive activity in any jurisdiction where benefits are claimed.
Industry practitioners and finance leaders will have an opportunity to explore these issues in more detail during an expert webinar on June 10, 2026. The online session will consider how the UAE framework compares with established regimes, structuring implications for groups with cross-border R&D, and practical points around substance, scalability and positioning. The session is targeted at tax directors, CFOs, corporate development leads and investors with exposure to innovation-driven businesses.
As the global competition for innovation talent and investment intensifies, the question for many organisations is evolving from whether to access incentives, to where R&D should be located to support long-term strategic goals.
